CN105456246A - Application of Lathyranone A in preparation of drug for treating rhinitis - Google Patents
Application of Lathyranone A in preparation of drug for treating rhinitis Download PDFInfo
- Publication number
- CN105456246A CN105456246A CN201510964292.5A CN201510964292A CN105456246A CN 105456246 A CN105456246 A CN 105456246A CN 201510964292 A CN201510964292 A CN 201510964292A CN 105456246 A CN105456246 A CN 105456246A
- Authority
- CN
- China
- Prior art keywords
- lathyranonea
- rhinitis
- lathyranone
- drug
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Lathyranone A for treating immune inflammation is used for preparing a drug for treating immune inflammation, and is particularly suitable for preparing a drug for treating rhinitis. By taking terfenadine and diclofenac sodium as contrasts, the Lathyranone A is clear in curative effect. The use of the related Lathyranone A in preparing the drug for treating rhinitis is disclosed for the first time; a skeleton type belongs to a brand new skeleton type, the strong activity in treating rhinitis is unexpected, and the possibility that another compound gives teaching does not exist, so outstanding substantive distinguishing features are achieved, and a remarkable improvement is obviously achieved when the Lathyranone A is used for preventing and treating rhinitis.
Description
Technical field
The present invention relates to the novelty teabag of compound L athyranoneA, particularly relate to the application of LathyranoneA in preparation treatment rhinitis medicine.
Background technology
Rhinitis is common clinical and frequently-occurring disease, and the generation of rhinitis is main relevant with anaphylaxis, belongs to the category of immune inflammation.At present, treatment rhinitis mainly adopt the antihistamine drug such as teldane or the Claritin such as tranilast, ketotifen, these medicines to the chronicity of rhinitis and recurrent exerbation curative effect poor or invalid.Therefore, definite ingredients, quality controllable and safely and efficiently micromolecular compound in development treatment of rhinitis medicine, there is potential value.
The compound L athyranoneA that the present invention relates to is one and delivers (SuoGao in 2007, etal., LathyranoneA:ADiterpenoidPossessinganUnprecedentedSkelet onfromEuphorbialathyris.ORGANICLETTERS, 2007, 9 (17): 3453-3455.) noval chemical compound, this compound has brand-new framework types (SuoGao, etal., LathyranoneA:ADiterpenoidPossessinganUnprecedentedSkelet onfromEuphorbialathyris.ORGANICLETTERS, 2007, 9 (17): 3453-3455.), the purposes of the LathyranoneA that the present invention relates in preparation treatment rhinitis medicine is belonged to first public, owing to belonging to brand-new structure type, and its activity for treatment rhinitis is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control simultaneously for rhinitis obviously has significant progress.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report of anti-rhinitis activity according in existing LathyranoneA research, provide LathyranoneA and preparing the application in anti-rhinitis medicament thing.
Described compound L athyranoneA, structure is as shown in formula I:
The application of described LathyranoneA in preparation treatment rhinitis medicine, LathyranoneA reduces the sneeze number of times of rhinitis rat caused by histamine.
One treats rhinitis medicine, and be that active component interpolation adjuvant is prepared from by LathyranoneA, preparation method, for getting 5 g of compound LathyranoneA, adds 195 grams, dextrin, and mixing, Conventional compression makes 1000.
One treats rhinitis medicine, and be that active component adds adjuvant and is prepared from by LathyranoneA, preparation method, for getting 5 g of compound LathyranoneA, adds starch 195 grams, and mixing, encapsulatedly makes 1000.
LathyranoneA10,20mg/kg oral administration, raises inhibited to scratch nose, sneeze reaction and nasal cavity vascular permeability of rat caused by antigen (ovalbumin) and histamine, therefore, can be used for the medicine preparing treatment rhinitis.
The purposes of LathyranoneA in preparation treatment rhinitis medicine belongs to first public, because framework types belongs to brand-new framework types, and its treatment rhinitis is active unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control simultaneously for rhinitis obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound L athyranoneA involved in the present invention is see document (SuoGao, etal., LathyranoneA:ADiterpenoidPossessinganUnprecedentedSkelet onfromEuphorbialathyris.ORGANICLETTERS, 2007,9 (17): 3453-3455.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L athyranoneA tablet involved in the present invention:
Get 5 g of compound LathyranoneA, add 195 grams, dextrin, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound L athyranoneA capsule involved in the present invention:
Get 5 g of compound LathyranoneA, add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example 1, LathyranoneA of the present invention cause the impact of rat allergic rhinitis on ovalbumin
Male SD rat, body weight 180 ~ 220g, lumbar injection ovalbumin 1mg and gel aluminum hydroxide 10mg, inject 1 time next day of thereafter, totally 7 times.Began from the 14th day, every day instills 1mg/ml ovalbumin normal saline solution 10ul at rat both sides nasal cavity, totally 7 times.Last is observed rat sneeze in 30 minutes at once and is wiped the number of times of nose after instiling, trial drug instils in ovalbumin last and orally to give for first 1 hour.
Table 1 LathyranoneA of the present invention causes the impact (x ± SD) of rat allergic rhinitis to ovalbumin
Compare with matched group, * * P<0.01*P<0.05
From table 1, LathyranoneA (10,20mg/kg) obviously suppresses the sneeze of allergic rhinitis rat caused by ovalbumin and nose reaction of scratching.Teldane 10mg/kg also presents significant inhibitory action.
Experimental example 2, LathyranoneA of the present invention are on the impact of the rat rhinitis that histamine causes
Male SD rat, body weight 180 ~ 220g, orally to give after trial drug 1 hour, and both sides nasal cavity instillation 1M histamine normal saline solution 10ul, observes the number of times of rat sneeze and wiping nose in 30 minutes.
Table 2 LathyranoneA of the present invention causes the impact (x ± SD) of rat rhinitis to histamine
Compare with matched group, * * P<0.01*P<0.05
From table 2, LathyranoneA of the present invention (10,20mg/kg) obviously reduces the sneeze number of times of rhinitis rat caused by histamine, to nose reaction of scratching in suppression trend.Teldane 10mg/kg is then in significant inhibitory action.
Conclusion: LathyranoneA oral administration, inhibited to scratch nose, sneeze reaction of rat caused by antigen (ovalbumin) and histamine, therefore, can be used for the medicine preparing treatment rhinitis.
Claims (4)
- The application of 1.LathyranoneA in treatment rhinitis medicine, described compound L athyranoneA structure is as shown in formula I:
- 2. the application of LathyranoneA in treatment rhinitis medicine as claimed in claim 1, is characterized in that LathyranoneA reduces the sneeze number of times of rhinitis rat caused by histamine.
- 3. treat a rhinitis medicine, it is characterized in that by LathyranoneA described in claim 1 being that active component interpolation adjuvant is prepared from, preparation method, for getting 5 g of compound LathyranoneA, adds 195 grams, dextrin, and mixing, Conventional compression makes 1000.
- 4. treat a rhinitis medicine, it is characterized in that by LathyranoneA described in claim 1 being that active component adds adjuvant and is prepared from, preparation method, for getting 5 g of compound LathyranoneA, adds starch 195 grams, mixing, encapsulatedly makes 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510964292.5A CN105456246A (en) | 2015-12-20 | 2015-12-20 | Application of Lathyranone A in preparation of drug for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510964292.5A CN105456246A (en) | 2015-12-20 | 2015-12-20 | Application of Lathyranone A in preparation of drug for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105456246A true CN105456246A (en) | 2016-04-06 |
Family
ID=55594713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510964292.5A Pending CN105456246A (en) | 2015-12-20 | 2015-12-20 | Application of Lathyranone A in preparation of drug for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105456246A (en) |
-
2015
- 2015-12-20 CN CN201510964292.5A patent/CN105456246A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585150B (en) | Use of Nitrosporeusines A in drugs for treating rhinitis | |
| CN105362274A (en) | Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals | |
| CN105456246A (en) | Application of Lathyranone A in preparation of drug for treating rhinitis | |
| CN103494826B (en) | The application of Phyllanthoid A in preparation treatment rhinitis medicine | |
| CN105287495A (en) | Application of Sphenostylisins C in preparation of drugs used for treating rhinitis | |
| CN105287545A (en) | Applications of Strynuxlines A in preparation of rhinitis treatment drugs | |
| CN102872034B (en) | Application of Gypensapogenin B in medicaments for treating rhinitis | |
| CN103463007A (en) | Application of racemosins A in preparation of medicine treating rhinitis | |
| CN103330712A (en) | Application of Myriberine A in preparation of a medicine for treating rhinitis | |
| CN103751170B (en) | The application of Trigoxyphin K in treatment rhinitis medicine | |
| CN105125533A (en) | Medicine for treating rhinitis and application thereof | |
| CN106491617A (en) | Applications of the Friedolanostanes in treatment rhinitis medicine is prepared | |
| CN103462999A (en) | Application of Neonectrolide A in preparing medicament for treating rhinitis | |
| CN106551936A (en) | One kind treats rhinitis medicine and its application | |
| CN103638007A (en) | Application of Hippolachnin A in medicine for treatment of rhinitis | |
| CN103585152A (en) | Application of Caesanines D in medicament for treating rhinitis | |
| CN103393699B (en) | The application of Chukrasone A in preparation treatment rhinitis medicine | |
| CN103372006B (en) | The application of Chukrasone B in preparation treatment rhinitis medicine | |
| CN106389404A (en) | Applications of Linderolide H in preparing medicines for treating rhinitis | |
| CN103271932A (en) | Applications of compound in preparing drug for treating rhinitis | |
| CN107865862A (en) | Apigenin is preparing the application in treating rhinitis medicine | |
| CN102988390B (en) | Application of Houttuynoid C for preparing medicine for treating rhinitis | |
| CN102988393B (en) | Application of Houttuynoid B for preparing medicine for treating rhinitis | |
| CN107865846A (en) | Isovitexin is preparing the application in treating rhinitis medicine | |
| CN103393646A (en) | Application of Sarcaboside A to medicament for treatment of rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160406 |